Literature DB >> 9462435

Involvement of superoxide dismutase and pyruvate:ferredoxin oxidoreductase in mechanisms of metronidazole resistance in Entamoeba histolytica.

N A Samarawickrema1, D M Brown, J A Upcroft, N Thammapalerd, P Upcroft.   

Abstract

Metronidazole resistance has been induced in an axenic strain of Entamoeba histolytica (HTH-56:MUTM) following continuous exposure to steadily increasing drug concentrations. The drug-resistant line is routinely maintained in normally lethal levels of metronidazole (10 microM). Resistance to this concentration of drug was developed over 177 days. Decreased pyruvate:ferredoxin oxidoreductase (PFOR) activity in anaerobic organisms is one mechanism of metronidazole resistance but in entamoeba, PFOR activity was not decreased in metronidazole-resistant parasites as determined by immunofluorescent assays and immunoblotting studies. 2-Oxoacid oxidoreductase activity, which appeared to be due to a single enzyme, PFOR, was evident with pyruvate as well as the alternative substrates, alpha-ketobutyrate, alpha-ketoglutarate and oxaloacetate. A marked increase in superoxide dismutase (SOD) activity was detected in metronidazole-resistant E. histolytica. Increased SOD activity has not previously been documented as a mechanism of drug resistance although SOD has been associated with a range of stress situations in other organisms.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9462435     DOI: 10.1093/jac/40.6.833

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  41 in total

Review 1.  Why metronidazole is active against both bacteria and parasites.

Authors:  J Samuelson
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

2.  Drug susceptibility testing of anaerobic protozoa.

Authors:  J A Upcroft; P Upcroft
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  In vitro activity of azithromycin and dirithromycin against axenic Entamoeba histolytica.

Authors:  S Ranque; B Molet; D Christmann; E Candolfi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-12       Impact factor: 3.267

Review 4.  Current therapeutics, their problems, and sulfur-containing-amino-acid metabolism as a novel target against infections by "amitochondriate" protozoan parasites.

Authors:  Vahab Ali; Tomoyoshi Nozaki
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

5.  Efficacy of new 5-nitroimidazoles against metronidazole-susceptible and -resistant Giardia, Trichomonas, and Entamoeba spp.

Authors:  J A Upcroft; R W Campbell; K Benakli; P Upcroft; P Vanelle
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

6.  Exposure to antibiotics induces expression of the Mycobacterium tuberculosis sigF gene: implications for chemotherapy against mycobacterial persistors.

Authors:  T M Michele; C Ko; W R Bishai
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

7.  Efficacy of antiamebic drugs in a mouse model.

Authors:  Stephen Becker; Paul Hoffman; Eric R Houpt
Journal:  Am J Trop Med Hyg       Date:  2011-04       Impact factor: 2.345

8.  Effects of miltefosine and other alkylphosphocholines on human intestinal parasite Entamoeba histolytica.

Authors:  K Seifert; M Duchêne; W H Wernsdorfer; H Kollaritsch; O Scheiner; G Wiedermann; T Hottkowitz; H Eibl
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

Review 9.  Understanding drug resistance in human intestinal protozoa.

Authors:  Hend Aly El-Taweel
Journal:  Parasitol Res       Date:  2015-03-19       Impact factor: 2.289

10.  Molecular modeling on pyruvate phosphate dikinase of Entamoeba histolytica and in silico virtual screening for novel inhibitors.

Authors:  Preyesh Stephen; Ramachandran Vijayan; Audesh Bhat; N Subbarao; R N K Bamezai
Journal:  J Comput Aided Mol Des       Date:  2007-08-21       Impact factor: 3.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.